You searched for "prostatic"
A new haemostatic agent in tubeless PCNL
Tubeless percutaneous nephrolithotomy (PCNL) is increasingly being used in carefully selected patients to reduce hospital stay and analgesia requirements, especially in those with little bleeding who become stone free or have insignificant residual fragments (usually <4mm). Various agents have been...Men with a susceptibility to prostate cancer: implications of ethnicity in PCa risk-prediction and diagnosis
The diagnostic and therapeutic landscapes of prostate cancer (PCa) have advanced at great pace in the past decade. However, disparities in access to care, clinical outcomes and representation in therapeutic, interventional and genomic studies continue to exist between Afro-Caribbean (AC)...PREDICT Prostate – individualised, evidence-based estimates of survival and treatment benefit
Earlier this year ‘PREDICT Prostate’ was launched online alongside a high-profile publication in PLOS Medicine. The prognostic model and decision-aid has been designed to inform treatment decision-making among men newly diagnosed with non-metastatic prostate cancer. David Thurtle and Vincent Gnanapragasam...Prostate cancer
Case 1 What is prostate specific antigen (PSA) and what is its function? According to the ERSPC Trial (at 13 years), what was the number needed to screen and diagnosed to prevent one prostate cancer death and what was the...
Advanced prostate cancer and chemotherapy
The treatment pathway for advanced prostate cancer is both puzzling and complex and varies from centre to centre in the UK. The National Prostate Cancer Audit Report 2019 for England and Wales shows that only a quarter of men with...
Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer
Despite prostate cancer being one of the most commonly diagnosed cancers worldwide, there remains a need for high-quality evidence regarding the optimal treatment choice. In this large population-based cohort study, using the PCBaSe Sweden dataset, Sooriakumaran and colleagues identified patients...
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer
Abiraterone acetate, the prodrug of abiraterone, blocks endogenous androgen synthesis by inhibiting cytochrome p-450c17, a critical enzyme in androgen biosynthesis. Its active D4A metabolite also has anti-tumour effects through possibly multiple mechanisms. 3-5% of men diagnosed with prostate cancer in...Nurse practitioner TRUS biopsy: training and preparation
As prostate cancer rates increase, many urology departments rely on multi-professional teams to diagnose and manage patients with prostate cancer. The aim of this article is to highlight the skills, training and preparation required for nurse practitioners to undertake trans-rectal...Urethroplasty: a review of indications, techniques and outcomes
Urethral stricture is the most common cause of lower urinary tract obstruction in men aged between 20 and 40, carrying an estimated overall prevalence of 0.5% in the UK [1] and results in around 17,000 hospital admissions annually [2]. Endoscopic...Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility study
Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...
Imaging and Intervention in Urinary Tract Infections and Urosepsis
Urinary tract infections (UTIs) are highly prevalent in the community and account for approximately 40% of hospital-acquired infections. Yet, they are often underestimated and under-diagnosed: as one chapter of this book is entitled, nothing is simple about acute pyelonephritis. This...
